Large-scale Study Finds No Significant Increase in Cancer Risk with JAK Inhibitors for Rheumatoid Arthritis Patients

A large international study shows no significant overall increase in cancer risk for rheumatoid arthritis patients treated with JAK inhibitors, supporting their continued use under careful monitoring.
Recent research presented at the EULAR 2025 Congress provides reassuring evidence regarding the safety of Janus kinase inhibitors (JAKi) in the treatment of rheumatoid arthritis (RA). The study analyzed data from over 53,000 treatment initiations across multiple registers, comparing the incidence of cancer among RA patients treated with JAKi, biologic disease-modifying anti-rheumatic drugs (bDMARDs), and other mechanisms of action (OMA). Overall, the study found no statistically significant difference in cancer risk between JAKi and established treatments like TNF inhibitors, even among high-risk subgroups aged 50 and older with cardiovascular risk factors. Additionally, the research explored keratinocyte cancer risks, noting an increased incidence of basal cell carcinoma in JAKi-treated patients compared to those on TNF inhibitors, suggesting the importance of skin monitoring for these patients. Furthermore, preliminary findings indicate that Glucagon-like peptide-1 receptor agonists (GLP-1RA), known for cardiovascular benefits in diabetes, may also reduce certain cardiovascular risks in RA patients on JAKi, though further validation is needed. These comprehensive insights contribute to understanding the safety profile of JAK inhibitors and highlight the importance of ongoing surveillance for skin cancer and cardiovascular events in RA therapy.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Link Between Mononucleosis and Increased Risk of Rare Liver Disease
New research reveals a strong link between infectious mononucleosis caused by Epstein-Barr virus and an increased risk of developing primary sclerosing cholangitis, a rare liver disease. The findings suggest that prevention of mono could reduce PSC risk, opening new avenues for treatment strategies.
Social, Cultural, and Economic Factors Influence Risk of Receiving Unsafe Medication
A national study reveals that social, cultural, and economic disparities significantly increase the risk of receiving unsafe or inappropriate medication, highlighting the need for targeted healthcare interventions.
'Gas station heroin': The dangerous drug sold as a dietary supplement causing overdoses and deaths
Tianeptine, known as 'gas station heroin,' is a dangerous substance illegally sold as a dietary supplement, linked to overdoses and fatalities. Learn about its risks and regulatory challenges.
Innovative Bioprinted Spinal Disks Pave the Way for Advanced Back Pain Treatments
Innovative bioprinting of human spinal disks offers new avenues for understanding and treating back pain, providing realistic models to improve regenerative therapies.